The shifting paradigm in autism: from a single label to personalized neuropharmacology
Autism research is entering a pivotal new phase, driven by a growing recognition of its profound biological and clinical heterogeneity. A recent analysis in Nature Mental Health argues that the traditional paradigm of a single diagnostic label is increasingly inadequate. The field is now challenged to incorporate a neurodiversity lens and embrace individual variability, which is a necessary step to improve research, clinical outcomes, and lives. This evolution signals a move towards more personalized approaches in understanding and potentially treating neurodevelopmental conditions.
Study Significance: For pharmacologists and researchers in psychopharmacology, this shift underscores the critical need for therapeutics that move beyond a one-size-fits-all model. It highlights the importance of pharmacogenomics and personalized medicine in developing future interventions, where drug efficacy and therapeutic windows may vary significantly across the autism spectrum. This conceptual advance could fundamentally reshape the design of clinical trials and the development of targeted neuropharmacological agents.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
